Larimar Therapeutics (NASDAQ:LRMR) Releases Earnings Results, Beats Estimates By $0.06 EPS

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06, FiscalAI reports.

Larimar Therapeutics Trading Down 0.7%

Shares of LRMR opened at $3.00 on Tuesday. The firm has a fifty day simple moving average of $2.92 and a 200 day simple moving average of $3.76. Larimar Therapeutics has a 12 month low of $1.91 and a 12 month high of $6.42. The stock has a market capitalization of $311.64 million, a price-to-earnings ratio of -1.54 and a beta of 0.73.

Wall Street Analysts Forecast Growth

LRMR has been the subject of several research analyst reports. Leerink Partners initiated coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They issued an “outperform” rating and a $13.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Wall Street Zen lowered Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Wedbush set a $9.00 target price on shares of Larimar Therapeutics in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $10.00.

Check Out Our Latest Stock Analysis on LRMR

Insider Buying and Selling

In related news, CFO Michael Celano bought 18,460 shares of the company’s stock in a transaction that occurred on Wednesday, November 11th. The shares were acquired at an average price of $2.71 per share, for a total transaction of $50,026.60. Following the completion of the acquisition, the chief financial officer owned 234,245 shares of the company’s stock, valued at approximately $634,803.95. The trade was a 8.55% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Carole Ben-Maimon purchased 18,050 shares of Larimar Therapeutics stock in a transaction that occurred on Wednesday, November 11th. The shares were bought at an average cost of $2.77 per share, with a total value of $49,998.50. Following the completion of the transaction, the chief executive officer directly owned 386,326 shares of the company’s stock, valued at approximately $1,070,123.02. The trade was a 4.90% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 140,810 shares of company stock worth $381,955 in the last three months. Insiders own 4.00% of the company’s stock.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Read More

Earnings History for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.